Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Period	TotalRevenue
2016-12-31	$16.48M
2017-12-31	$26.12M
2018-12-31	$30.43M
2019-12-31	$43.10M
2020-12-31	$57.99M
2021-12-31	$33.05M
2022-12-31	$52.12M
2023-12-31	$36.27M
2024-12-31	$57.88M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NTLA	$13.85	+2.18%	2.13M
3
4
5

Intellia Therapeutics Inc. (NTLA) Revenue History

Revenue Data

Get Intellia Therapeutics Inc. Data in Excel

More NTLA Financial Data